Ascendis Pharma A/S

ASNDNASDAQ · USD
275.39USD0.00 (+3.12%)
642

Ascendis Pharma A/S (ASND) Option Chain

Ascendis Pharma A/S trades at $275.39, up 3.12%, with an IV Rank of 1.59%. This is low versus the past year, and the company carries a market cap of $18,085M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $280.00 strike shows calls at $1.50 / $5.40 and puts at $5.90 / $9.20, both carrying about $3.19 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $290.00 calls, at 103 contracts, and the $270.00 puts, at 4, as of Nov 13, 2026.

Read more

Tracking the ASND option chain helps you see every strike and expiry on Ascendis Pharma A/S in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ASND options activity at a glance. Use our scanner to monitor the ASND option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ASND stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where ASND options are being actively traded, and where they are not.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
10.9669221.2615.3915.1018.20260.00-5.59—3.800.003.8002789.04
33.8060133.215.397.0010.20270.00-1.961.003.300.002.154466.20
64.192033.450.001.505.40280.00+1.675.909.204.612.940035.81
86.81361032.000.00—2.00290.00+5.3113.8016.8014.610.690013.19
96.7510503.600.00—3.60300.00+8.9423.3026.3024.610.19013.25

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank1.59% Low
  • Market cap (M$)18,085
  • 52 weeks high-2.40%
  • 52 weeks low46.42%
  • Analyst recommendationStrong Buy
    1.18
  • Target price$316.26
    14.84% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2027-02-10
  • P/E17.73
  • Future P/E24.81
  • EPS (ttm)15.54
  • EPS growth next 5 years—

As of Nov 13, 2026